All In Biotech

Drug Trial Radar · NCT06191744

Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma

A Phase 3, Multicenter, Randomized, Open-Label Trial to Evaluate the Safety and Efficacy of Epcoritamab + Rituximab and Lenalidomide (R2) Compared to Chemoimmunotherapy in Previously Untreated Follicular Lymphoma (EPCORE™FL-2)

Last checked: Nov 19, 2026Latest source record: Aug 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 1,095 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

1,095

Actual

Start

Feb 5, 2024

Primary completion

Nov 2037

Study completion Nov 2037

Sponsor

Lead sponsor
GenmabIndustry
Sponsor type
Industry
Collaborators
AbbVie
First posted
Jan 5, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Follicular lymphoma (FL) is the second most common B-cell cancer and the most common type of cancer of lymphocytes. Unfortunately, this disease is incurable with conventional treatment and the disease recurs in almost all patients. This study will assess how safe and effective epcoritamab is in combination with lenalidomide and rituximab (R2) in treating adult participants with previously untreated FL. Adverse events and change in disease condition will be assessed. Epcoritamab is an investigational drug being developed for the treatment of FL. Study doctors put the participants in 1 of 5 groups, called treatment arms. Each group receives a different treatment. Around 1095 adult participants with previously untreated FL will be enrolled in approximately 250 sites across the world. Participants will receive R2 (intravenous \[IV\] infusion of rituximab (R) and oral capsules of lenalidomide) alone or in combination with subcutaneous injections of epcoritamab. Participants may also receive investigator's choice chemoimmunotherapy (CIT): IV infusion of obinutuzumab (G) and IV injections of cyclophosphamide, IV injections of doxorubicin, IV injections of vincristine, oral tablets of prednisone (CHOP) \[G-CHOP\]/ R-CHOP or G and IV infusion of bendamustine (Benda) \[G-Benda\]/R-Benda. The total treatment duration will be 120 weeks for all arms except A2, which is 24 weeks of treatment. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

Conditions

  • Follicular Lymphoma (FL)

Interventions

  • EpcoritamabDrug

    Subcutaneous (SC) Injection

  • PrednisoneDrug

    Oral Tablet

  • RituximabDrug

    Intravenous (IV) Infusion

  • LenalidomideDrug

    Oral Capsule

  • DoxorubicinDrug

    IV Injection

  • VincristineDrug

    IV Injection

  • CyclophosphamideDrug

    IV Injection

  • ObinutuzumabDrug

    IV Infusion

  • BendamustineDrug

    IV Infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Arm A1 vs Arm B: Percentage of Participants who Achieve Complete Response rate at 30 months (CR30)Time frame: Up to 30 Months
  2. Arm A1 vs Arm B: Number of Participants with Progression-free survival (PFS)Time frame: Up to 10 Years

Locations

266 sites in 32 countries. Site status is shown where the registry gives one.

  • UCSF Fresno /ID# 264712

    Fresno, California

  • Scripps Mercy Hospital /ID# 265393

    San Diego, California

  • Sansum Clinic Research /ID# 261596

    Santa Barbara, California

  • Rocky Mountain Cancer Centers - Boulder /ID# 261203

    Boulder, Colorado

  • Christiana Care Health Service /ID# 261207

    Newark, Delaware

  • Cancer Specialists of North Florida - Jacksonville - AC Skinner Parkway /ID# 262445

    Jacksonville, Florida

  • Advent Health /ID# 261578

    Orlando, Florida

  • Orlando Health Cancer Institute /ID# 260983

    Orlando, Florida

  • Moffitt Cancer Center /ID# 259487

    Tampa, Florida

  • Beacon Cancer Care - Coeur d'Alene /ID# 260670

    Coeur d'Alene, Idaho

  • Northwestern Medicine - Northwestern Memorial Hospital /ID# 259814

    Chicago, Illinois

  • Cancer Care Specialists Of Central Illinois /ID# 272464

    Decatur, Illinois

  • Loyola University /ID# 259462

    Maywood, Illinois

  • Illinois Cancer Care, PC /ID# 261526

    Peoria, Illinois

  • Fort Wayne Medical Oncology and Hematology- South Office /ID# 259583

    Fort Wayne, Indiana

  • University of Iowa Health Care /ID# 262132

    Des Moines, Iowa

  • University of Louisville Hospital /ID# 260544

    Louisville, Kentucky

  • Norton Cancer Institute - St. Matthews /ID# 261076

    Louisville, Kentucky

  • New England Cancer Specialists - Westbrook /ID# 260672

    Westbrook, Maine

  • University of Maryland, Baltimore /ID# 259538

    Baltimore, Maryland

  • Center for Cancer and Blood Disorders-American Oncology Partners of Maryland /ID# 259476

    Bethesda, Maryland

  • St. Luke's Hospital - Chesterfield /ID# 260489

    Chesterfield, Missouri

  • Intermountain Health St Vincent Regional Hospital - Cancer Centers of Montana /ID# 260006

    Billings, Montana

  • Nebraska Cancer Specialists (NCS) - Regional Cancer Center - St Francis Location /ID# 262506

    Grand Island, Nebraska

  • Nebraska Hematology-Oncology /ID# 269692

    Lincoln, Nebraska

  • Nebraska Cancer Specialists - Omaha - Wright Street /ID# 262505

    Omaha, Nebraska

  • University of Nebraska Medical Center /ID# 261996

    Omaha, Nebraska

  • University of New Mexico /ID# 261083

    Albuquerque, New Mexico

  • Presbyterian Kaseman Hospital /ID# 262451

    Albuquerque, New Mexico

  • Presbyterian Rust Medical Center /ID# 262447

    Rio Rancho, New Mexico

  • New York Oncology Hematology - Albany Cancer Center /ID# 261814

    Albany, New York

  • NYU Langone Hospital - Long Island /ID# 265531

    Mineola, New York

  • NYU Langone Medical Center /ID# 264518

    New York, New York

  • Icahn School of Medicine at Mount Sinai /ID# 259595

    New York, New York

  • New York Oncology Hematology /ID# 270208

    Troy, New York

  • Clinical Research Alliance - Westbury /ID# 261078

    Westbury, New York

  • Novant Health Presbyterian Medical Center /ID# 259740

    Charlotte, North Carolina

  • Novant Health Forsyth Medical Center /ID# 259741

    Winston-Salem, North Carolina

  • Oncology Hematology Care, Inc - Blue Ash /ID# 261204

    Cincinnati, Ohio

  • Taylor Cancer Research Center /ID# 260488

    Maumee, Ohio

Showing 40 of 266 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.